From tau phosphorylation to tau aggregation: what about neuronal death?
暂无分享,去创建一个
R. D'Hooge | L. Buée | D. Balschun | A. Van der Jeugd | N. Sergeant | C. Maurage | D. Blum | K. Bélarbi | V. Buée-Scherrer | F. Fernández-Gómez | H. Obriot | M. Hamdane | R. Caillierez | T. Ahmed | S. Bégard | D. Demeyer | L. Troquier | S. Burnouf | M. Grosjean | Bérangère Barbot | I. Brion | K. Belarbi
[1] P. Hof,et al. Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.
[2] P. Hof,et al. Pathological τ proteins in postencephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders , 1997 .
[3] M. Garcia-Blanco,et al. Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing , 2009, Human molecular genetics.
[4] D. Campion,et al. Inhibition of proteasome and Shaggy/Glycogen synthase kinase‐3β kinase prevents clearance of phosphorylated tau in Drosophila , 2006, Journal of neuroscience research.
[5] L. Buée,et al. Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation , 2007, Genes, brain, and behavior.
[6] M. Goedert,et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.
[7] Alexandra Flemming,et al. Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.
[8] A. Delacourte,et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease , 2005, Neurology.
[9] L. Buée,et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. , 2010, Journal of Alzheimer's disease : JAD.
[10] T. Cooper,et al. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats , 2008, Experimental Neurology.
[11] P. Davies,et al. Anesthesia-Induced Hyperphosphorylation Detaches 3-Repeat Tau from Microtubules without Affecting Their Stability In Vivo , 2008, The Journal of Neuroscience.
[12] L. Buée,et al. Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology? , 2011, Current Alzheimer research.
[13] G. Schellenberg,et al. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. , 2009, Human molecular genetics.
[14] Y. Barde,et al. Neurotrophins are required for nerve growth during development , 2001, Nature Neuroscience.
[15] H. Hutter,et al. A Caenorhabditis elegans model of tau hyperphosphorylation: Induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau , 2009, Neurobiology of Aging.
[16] A. Delacourte,et al. Specific tau variants in the brains of patients with myotonic dystrophy , 1996, Neurology.
[17] R. Brandt,et al. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain , 1995, The Journal of cell biology.
[18] D. Campion,et al. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. , 2007, Human molecular genetics.
[19] G. Schellenberg,et al. Tau isoform regulation is region‐ and cell‐specific in mouse brain , 2008, The Journal of comparative neurology.
[20] A. Delacourte,et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. , 2001, Human molecular genetics.
[21] P. Davies,et al. Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes , 2000, Neurobiology of Disease.
[22] D. Geschwind,et al. Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.
[23] A. Delacourte,et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. , 2001, Human molecular genetics.
[24] J. Trojanowski,et al. Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.
[25] L. Buée,et al. Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. , 2009, Current Alzheimer research.
[26] Andrew H Crosby,et al. Disruption of cellular transport: a common cause of neurodegeneration? , 2003, The Lancet Neurology.
[27] Joshua M. Shulman,et al. Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.
[28] W. Noble,et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] H. Bujard,et al. The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy , 2008, The Journal of Neuroscience.
[30] M. Vitek,et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.
[31] L. Buée,et al. P1–062: Alzheimer's disease–like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits , 2006, The American journal of pathology.
[32] L. Buée,et al. Exploring the molecular function of PIN1 by nuclear magnetic resonance. , 2006, Current protein & peptide science.
[33] E. Elliott,et al. BAG-1 Associates with Hsc70·Tau Complex and Regulates the Proteasomal Degradation of Tau Protein* , 2007, Journal of Biological Chemistry.
[34] A. Delacourte,et al. Biochemistry of Tau in Alzheimer’s disease and related neurological disorders , 2008, Expert review of proteomics.
[35] Charles Duyckaerts,et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. , 2002, Brain : a journal of neurology.
[36] R. Crowther,et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.
[37] M. Goedert,et al. Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases in intact cells , 2002, FEBS letters.
[38] S. Lovestone,et al. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.
[39] Patrick R. Hof,et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.
[40] P. Hof,et al. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. , 1995, The American journal of pathology.
[41] H. Geerts,et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.
[42] R. Nelson,et al. Anesthesia Leads to Tau Hyperphosphorylation through Inhibition of Phosphatase Activity by Hypothermia , 2007, The Journal of Neuroscience.
[43] S Lovestone,et al. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.
[44] D. Wilson,et al. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. , 1997, The American journal of pathology.
[45] M. Mercken,et al. Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.
[46] S. Lovestone,et al. Erratum: GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila (Molecular Psychiatry (2004) 9 (522-530) DOI:10.1038/sj.mp.4001483) , 2004 .
[47] J. Brion,et al. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. , 1999, The American journal of pathology.
[48] Gerard D Schellenberg,et al. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. , 2006, Human molecular genetics.
[49] A. Delacourte,et al. Tau protein as a differential biomarker of tauopathies. , 2005, Biochimica et biophysica acta.